Slide 1: Corporate Presentation
Corporate Presentation March 2026 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking” statements within the These forward-looking statements are made in light of information meaning of applicable securities laws, including the Private Securities currently available to us and are subject to numerous risks and Liti
Slide 3: Cellectis' Leadership Position in Cell & Gene Therapy
Cellectis’ Leadership Position in Cell & Gene Therapy BEST-IN-CLASS INNOVATIVE END-TO-END STRONG GENE EDITING ALLOGENEIC CAR-T IN-HOUSE PARTNERSHIPS PLATFORM MANUFACTURING 4 ongoing clinical trials*: Diversified Financial Backed by Strong IP and (2 in Pivotal Phase II and Upsides Know-How 2 in Phase
Slide 4: Cash Position & Partnerships
Cash Position & Partnerships Partnerships with industry leaders: Multi-billion potential milestones ClinicalCash Trials* Position* + royalties $211M as of December 31, 2025 Expected runway into H2 2027 * Cash position i.e. cash, cash equivalents and fixed-term deposits include restricted cash of $4.
Slide 5: TALEN is Best-in-class Gene Editing
TALEN® is Best-in-class Gene Editing NUCLEASE SAFE Low genotoxicity and off-target* Gene replacement, correction, insertion PRECISE Targets precisely any DNA BASE EDITORS Gene editing without CRISPR- associated genotoxicity EFFICIENT High editing efficiencies (up to 100%) GENE MODULATORS VERSATILE V
Slide 6: UCART Design
UCART Design CD52 KO TCRaβ KO CAR CD52 KO TCRaβ KO Resistance to Minimizes risk CAR-T cell anti-CD52 abs of GvHD Abs: Antibodies ; CART: Chimeric Antigen Receptor T-cell ; GvHD: Graft-versus-Host-Disease ; KO: Knock-Out ; UCART: Universal Chimeric Antigen Receptor T-cell 6
Slide 7: Allogeneic CAR-T: Unlocking a Scalable Industrial Approach
Allogeneic CAR-T: Unlocking a Scalable Industrial Approach Healthy donor Cell Cell Frozen UCART Patients cell collection modification amplification product Scalable Manufacturing Off-The-Shelf 1 batch = 100s doses Immediate access and Scalable to 1000s doses attractive gross margins 7
Slide 8: Fully Integrated Manufacturing
Fully Integrated Manufacturing Paris, France Raleigh, NC CMC Development, UCART – Clinical & Intended Starting Materials Commercial Ready Site ✓ Process & analytical development ✓ UCART GMP manufacturing Allogeneic CAR-T ✓ Starting materials manufacturing: ✓ QC testing labs ➢ Buffers, ➢ Plasmids, ✓
Slide 9: Advancing an Industry-Leading Pipeline
Advancing an Industry-Leading Pipeline INDICATION / STUDY PRECLINICAL PHASE 1 PHASE 21 UPCOMING EXPECTED MILESTONE TYPE FULLY OWNED BALLI-01 B-ALL Pivotal Phase 2 first interim analysis Lasme-cel (CD22) (Allogeneic CAR-T) expected in Q4 2026 NATHALI-01 NHL Full Phase 1 dataset Eti-cel (CD20, CD22) (
Slide 10: Lasme-cel and Eti-cel Differentiated Positioning
Lasme-cel and Eti-cel Differentiated Positioning Post-CD19 CAR-T autologous treatments KITE-363/ KITE-753 JNJ-4496 CD19/CD20 CD19/CD20 ▪ CD20 & CD22: Differentiated targets validated in oncology AUTO 1/22 Ronde-cel CD19/CD22 CD19/CD20 ▪ Lasme-cel: Best-in-class allogeneic CD22 CAR-T for B-ALL. ▪ Eti
Slide 11: Lasme-cel for patients with relapsed or refractory B-ALL
Lasme-cel for patients with relapsed or refractory B-ALL Lasme-cel is not approved for commercialization 11
Slide 12: B-ALL: an Unmet Medical Need
B-ALL: an Unmet Medical Need B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA • 1L treated population: ~9,200 Patients (US, EU4, UK)* High relapse in adults CHALLENGES WITH EXISTING TREATMENTS • Chemotherapies: Lead to high relapse rate in adults • ADCs have a limited effect: Low antigen expression • CD19-direct
Slide 13: Why an Allogeneic CD22 CAR-T cell Product for r/r B-ALL?
Why an Allogeneic CD22 CAR-T cell Product for r/r B-ALL? Allogeneic CAR-T Starts with Healthy-donor T Cells Healthier and less exhausted than autologous cells from heavily pretreated patients Off-the-Shelf is designed for “Speed” – in B-ALL Every Day Counts Standardized, Repeatable Quality All patie
Slide 14: Poor Response Rates after Targeted Therapy Failure
Poor Response Rates after Targeted Therapy Failure 1 After targeted therapy failure, salvage chemo yields low ORR and MRD: High unmet need in heavily Post Blina failure Post Ino failure Post CAR-T failure pretreated patients ORR <20% ORR <10-15% ORR <10% MRD-ve <10% MRD-ve <5-10% MRD-ve <5% 1. Inter
Slide 15: BALLI | Demographic and Baseline Characteristics
BALLI 01 | Demographic and Baseline Characteristics DL3 P2 All Subjects (n=12) Age ≤ 50 (n=9) Total (n=40) Age (yrs), median (range) 27 (16 - 66) 23 (16 - 45) 27 (16 - 68) Sex, n (%) Male 5 (41.7) 3 (33.3) 22 (55) Female 7 (58.3) 6 (66.7) 18 (45) ECOG PS, n (%) 0 5 (41.7) 4 (44.4) 14 (35) 1 6 (50) 4
Slide 16: High Response Rates in P2 Cohort
High Response Rates in P2 Cohort Overall Response Rate (%) 100% 100 90 83% Cellectis manufactured 80 68% 44% product (P2) is superior Percentage % 70 41% to CDMO product (P1) 60 50 32% 40 28% Recommended Phase 2 30 56% Dose: DL3 6% 20 36% 42% 10 22% Target Phase 2 0 P1(n=18) P1 (n=18 P2 (n=22) P2 DL
Slide 17: High Response Rates in P2 Cohort
High Response Rates in P2 Cohort CR/CRi rate with MRD status (%) 60 56% 56% 50 11% 42% 42% Percentage % 40 36% 36% In Target Phase 2 8% 9% population, 30 22% 22% 80% who achieved 45% 20 CR/CRi were also 11% 34% 27% MRD negative 10 11% 0 P1 (n=18 (n=18) P2 (n=22) P2 DL3 (n=12) Target Pivotal Phase 2
Slide 18: Achieving Transplant: an Important Clinical Outcome
Achieving Transplant: an Important Clinical Outcome 100% Received or Eligible for HSCT In Phase 2 target population 18
Slide 19: Improved Survival in Patients Who Responded
Improved Survival in Patients Who Responded Overall Survival over 12 months by Response Median Overall Survival in Subjects who Achieve MRD- negative CR/CRi 16 14.8 14.8 14 12 10 9.4 Months 8 6 4 2 0 P2 DL3 Target Pivotal Phase 2 Population P2 14.8 months DL3 Median overall survival in subjects who
Slide 20: High CR/CRi Rates in Patients Exposed to Prior Targeted Therapies
High CR/CRi Rates in Patients Exposed to 3 Prior Targeted Therapies: Inotuzumab, Blinatumomab and CD19 CAR-T CR/CRi Rate (in %) in Patients with Prior Exposure to 3 Targeted Therapies: Blin, Ino and CD19 CAR-T 80 70 Deep 60 responses if 50 received all 3 available 40 75% targeted 30 60% therapies 20
Slide 21: Low Incidence of Grade ≥ CRS and ICANS
P21 Low Incidence of Grade ≥ 3 CRS and ICANS CRS and ICANS: DL3 (n=18) CRS and ICANS: Total Population (n=40) 100 100 90 90 80 5.5 80 70 70 2.5 Percentage (%) Percentage (%) 60 39 60 32.5 50 50 40 40 12 30 30 12 20 39 20 37.5 5 10 10 17 10 7.5 0 0 CRS ICANS CRS ICANS Grade1 Grade 2 Grade 3 Grade1 Gr
Slide 22: Study Design: Pivotal Phase 2
Study Design: Pivotal Phase 2 Primary Endpoint: Recruitment of patients driven by 75 planned study centers in CR / CRi, evaluated within North America and Europe 3 months (from Day 28 to Day 84) Age 12-50 years LD: Lymphodepletion; RP2D: Recommended Phase 2 Dose 22
Slide 23: Multiple Catalysts to 2H 2028
Clear Registration Path to BLA Submission Targeted For 2028: Key Anticipated Milestones 4Q 2026 2Q 2027 3Q 2027 1Q 2028 2H 2028 BLA Interim Interim Enrollment Primary Submission Analysis 1 Analysis 2 Completed Analysis 40 Patient dose 50% Pivotal Cohort Completed optimization Multiple Catalysts to 2
Slide 24: Lasme-cel Has the Potential to Reach Up To ~1.9 K Addressable 3L+ Patients
Lasme-cel Has the Potential to Reach Up To ~1.9 K Addressable 3L+ Patients U.S. and EU4+UK 2035E Lasme-cel Addressable Population Incident 1L Treated B-ALL Population (2035E) ~9.2 K Patients (~5.1 K U.S. + ~4.1 K EU4+UK) Of the ~9.2 K expected B-ALL patients, ~45% are expected to progress to 2L, ~45
Slide 25: Lasme-cel Could Achieve Up To ~$700 M in Peak Gross Sales
Lasme-cel Could Achieve Up To ~$700 M in Peak Gross Sales (U.S., EU4, UK) Assumption Source / Rationale Addressable Patients (#) ~1.1 K ~840 Represents expected 3L CAR-T eligible patients in 2035 x x • Triangulated using physician-reported preferences and average market share of Preference Share (%)
Slide 26: Eti-cel for patients with relapsed or refractory NHL
Eti-cel for patients with relapsed or refractory NHL Eti-cel is not approved for commercialization 26
Slide 27: Eti-cel: Study Design
Eti-cel: Study Design Dose Escalation Key inclusion criteria: Dose Expansion ▪ Age 18–80 years BOIN design • 2-4 pts/cohort ▪ Mature B-cell NHL except CLL/SLL, Richter’s from CLL/SLL, Burkitt’s lymphoma, or Waldenstrom’s macroglobulinemia 450 × 10 6 cells DL 3 ▪ Tumor positive for CD20 and/or CD22 ▪
Slide 28: Eti-cel: High Response Rates in R/R NHL
Eti-cel: High Response Rates in R/R NHL Response rate at current dose level (%) n=8 100 90 80 70 Percentage % 60 5/8 CR at 50 current 88% 40 dose level 30 63% 20 10 0 ORR CR Presented at ASH 2025 28 ASH: American Society of Hematology Annual Meeting
Slide 29: Expected 2026 Catalysts
Expected 2026 Catalysts Lasme-cel Pivotal Phase 2 First Interim Analysis Eti-cel Full Phase 1 Dataset Preclinical PoC for In Vivo Gene Therapy PoC: Proof-of-Concept 29
Slide 30: Thank You
Thank You Reach us at: investors@cellectis.com Cellectis Paris Cellectis New York Cellectis Raleigh 8, rue de la Croix Jarry 75013 430 East 29th Street 2500 Sumner Boulevard Paris – France New York, NY, 10016 – USA Raleigh, NC, 27616 – USA Cellectis®, TALEN® and our corporate logos are registered tr
Slide 31: Diversified Partnerships with Industry Leaders
Diversified Partnerships with Industry Leaders CAR-T CAR-T BCMA, CD70 TILs Cell and Gene Therapies CD19 (cema-cel) + 13 targets Exclusive U.S. rights Exclusive Research Joint Research and worldwide license exclusively worldwide license collaboration and Collaboration to CD19-directed sublicensed to